Purple Biotech (PPBT) Accumulated Expenses (2015 - 2025)

Purple Biotech (PPBT) has 10 years of Accumulated Expenses data on file, last reported at $797000.0 in Q4 2025.

• On a quarterly basis, Accumulated Expenses rose 15.17% year-over-year to $797000.0 in Q4 2025; TTM through Dec 2025 was $797000.0, a 15.17% increase from a year earlier, with the FY2025 full-year figure at $797000.0, up 15.17% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $797000.0, up from $692000.0 in the prior quarter.
• Over the last five years, Accumulated Expenses for PPBT reached as high as $3.6 million in Q4 2022 and fell as low as -$859000.0 in Q1 2021.
• Historically, Accumulated Expenses has averaged $633111.1 across 5 years, with a median of $692000.0 in 2024.
• Across the five-year window, Accumulated Expenses jumped 135.56% in 2022 and tumbled 72.55% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $1.5 million in 2021, then soared by 135.56% to $3.6 million in 2022, then dropped by 29.91% to $2.5 million in 2023, then tumbled by 72.55% to $692000.0 in 2024, then advanced by 15.17% to $797000.0 in 2025.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $797000.0 in Q4 2025, $692000.0 in Q4 2024, and $2.5 million in Q4 2023.